Matthias Kromayer
Vorstandsvorsitzender bei Tavia Consulting GmbH
Profil
Matthias Kromayer currently works at BIOCRATES Life Sciences AG, as Deputy Chairman-Supervisory Board, AMSilk GmbH, as Vice Chairman-Supervisory Board, Immatics US, Inc., as Director, Tavia Consulting GmbH, as Managing Director, MIG Verwaltungs AG, as General Partner & Board Member from 2010, Ci3 Management UG, as Member, apceth Biopharma GmbH, as Member-Supervisory Board, and iOmx Therapeutics AG, as Member-Supervisory Board from 2022.
Dr. Kromayer also formerly worked at ViroLogik GmbH, as Chief Executive Officer, cerbomed GmbH, as Chairman, Nexigen GmbH, as Chairman-Advisory Board & Director, Immatics Biotechnologies GmbH, as Member-Supervisory Board in 2013, and BRAIN Biotech AG, as Member-Supervisory Board from 2011 to 2017.
Dr. Kromayer received his undergraduate degree and doctorate degree from Ludwig-Maximilians-Universität München.
Aktive Positionen von Matthias Kromayer
Unternehmen | Position | Beginn |
---|---|---|
MIG Verwaltungs AG
MIG Verwaltungs AG Investment ManagersFinance MIG Verwaltungs AG is a private equity investment firm headquartered in Munich, Germany. It was founded in 2004 by entrepreneurs and financial institutions, to follow up on the success of the venture capital investment vehicles Global Chance Fund and Global Asset Fund, with which MIG's management had been involved. | Private Equity Investor | 09.02.2010 |
AMSilk GmbH
AMSilk GmbH TextilesProcess Industries AMSilk GmbH engages in the production of fiber and biopolymers.It offers implant coating, medical devices for OTC wound care, functional cosmetics, cell biology device kits, biosteel spidersilk fibers and spidersilk research license. It serves the biosteel fibers, medical devices, and cosmetic ingredients industry. The firm's materials are to be applied in numerous fields to improve existing products or to develop materials for completely new applications, which could not be realized until now due to the lack of an appropriate material. The company was founded by Axel H. Leimer, Thomas Scheibel, and Lin Römer in 2008 and is headquartered in Planegg, Germany. | Direktor/Vorstandsmitglied | - |
Tavia Consulting GmbH | Vorstandsvorsitzender | - |
BIOCRATES Life Sciences AG
BIOCRATES Life Sciences AG BiotechnologyHealth Technology BIOCRATES Life Sciences AG operates as a research and technology. It provides metabolic phenotyping services. The firm products are absoluteIDQ p150 kit, p180 kit, sterio17 kit, steroid reagents, biocrates bile acids kit, and steroid kit. The company was founded by Gunther Bonn, Adelbert Roscher, and Hartmut Glossmann in 2002 and is headquartered in Innsbruck, Austria. | Direktor/Vorstandsmitglied | - |
Ci3 Management UG | Corporate Officer/Principal | - |
Immatics US, Inc.
Immatics US, Inc. BiotechnologyHealth Technology Immatics US, Inc. develops adoptive cell therapies (ACT) for the treatment of cancer. The company’s ACT therapies are intended to use human T-cells that have been multiplied outside the body before being infused into a cancer patient. It also offers XPRESIDENT, a target discovery engine that enables users to identify, quantify, and prioritize tumor-associated peptides that are recognized by T-cells. The company was founded by Harpreet Singh-Jasuja, Toni Weinschenk, Niels Emmerich, Hans-George Rammensee, Steffen Walter, Peter Brossart and Hansjorg Schild in June 2015 and is headquartered in Houston, TX. | Direktor/Vorstandsmitglied | - |
Minaris Regenerative Medicine GmbH
Minaris Regenerative Medicine GmbH BiotechnologyHealth Technology apceth Biopharma GmbH operates as a contract development & manufacturing organization. The firm specializes in cell-based and gene therapy products (Advanced Therapy Medicinal Products, ATMPs). Its GMP services include quality management, quality control, assay development, process development, cell banking & formulation and project management. The company was founded in 2007 and is headquartered in Munich, Germany. | Direktor/Vorstandsmitglied | - |
iOmx Therapeutics AG
iOmx Therapeutics AG BiotechnologyHealth Technology iOmx Therapeutics AG develops immunotherapy treatments for cancer patients. It specializes in immuno oncology, drug development and cancer therapy. The company was founded by Nisit Khandelwal, Philipp Beckhove, Patrick Baeuerle, Sebastian Meier-Ewert and Elmar Maier in March 2016 and is headquartered in Munich, Germany. | Direktor/Vorstandsmitglied | 20.07.2022 |
Ehemalige bekannte Positionen von Matthias Kromayer
Unternehmen | Position | Ende |
---|---|---|
BRAIN BIOTECH AG | Direktor/Vorstandsmitglied | 09.03.2017 |
░░░░░░░░ ░░░░ | ░░░░░░░░░░░░ | - |
░░░░░░░░ ░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░░░░░░░░░░░ | - |
░░░░░░░ ░░░░ | ░░░░░░░░░░░░ | - |
░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░░░░░░ | - |
Ausbildung von Matthias Kromayer
Ludwig-Maximilians-Universität München | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
BRAIN BIOTECH AG | Health Technology |
Private Unternehmen | 12 |
---|---|
ViroLogik GmbH
ViroLogik GmbH Pharmaceuticals: MajorHealth Technology ViroLogik GmbH develops drugs for treatment of viral diseases. It is developing a novel strategy to prevent formation of drug resistance in case of Hepatitis C and HIV infections. The company was founded in 2006 by Ulrich Schubert and is headquartered in Jena, Germany. | Health Technology |
MIG Verwaltungs AG
MIG Verwaltungs AG Investment ManagersFinance MIG Verwaltungs AG is a private equity investment firm headquartered in Munich, Germany. It was founded in 2004 by entrepreneurs and financial institutions, to follow up on the success of the venture capital investment vehicles Global Chance Fund and Global Asset Fund, with which MIG's management had been involved. | Finance |
Immatics Biotechnologies GmbH
Immatics Biotechnologies GmbH Pharmaceuticals: MajorHealth Technology Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany. | Health Technology |
AMSilk GmbH
AMSilk GmbH TextilesProcess Industries AMSilk GmbH engages in the production of fiber and biopolymers.It offers implant coating, medical devices for OTC wound care, functional cosmetics, cell biology device kits, biosteel spidersilk fibers and spidersilk research license. It serves the biosteel fibers, medical devices, and cosmetic ingredients industry. The firm's materials are to be applied in numerous fields to improve existing products or to develop materials for completely new applications, which could not be realized until now due to the lack of an appropriate material. The company was founded by Axel H. Leimer, Thomas Scheibel, and Lin Römer in 2008 and is headquartered in Planegg, Germany. | Process Industries |
Nexigen GmbH
Nexigen GmbH Pharmaceuticals: MajorHealth Technology Nexigen GmbH identifies and develops peptide based therapeutics for cancer. It focuses on the development of pathways to create transformative cancer therapies. The firm's technologies give access to drug targets which pose significant challenges to conventional discovery approaches. The company was founded by Annette Friebe, Burckhard Heil, and Claudia Carl in 2007 and is headquartered in Cologne, Germany. | Health Technology |
Tavia Consulting GmbH | |
BIOCRATES Life Sciences AG
BIOCRATES Life Sciences AG BiotechnologyHealth Technology BIOCRATES Life Sciences AG operates as a research and technology. It provides metabolic phenotyping services. The firm products are absoluteIDQ p150 kit, p180 kit, sterio17 kit, steroid reagents, biocrates bile acids kit, and steroid kit. The company was founded by Gunther Bonn, Adelbert Roscher, and Hartmut Glossmann in 2002 and is headquartered in Innsbruck, Austria. | Health Technology |
Ci3 Management UG | |
cerbomed GmbH
cerbomed GmbH Medical SpecialtiesHealth Technology cerbomed GmbH manufactures and supplies medical devices for treating epilepsy. It offers NEMOS, a transcutaneous vagus nerve stimulation unit that treats epilepsy patients. The company was founded by Stefan Dietrich and Timo Freitag in 2005 and is headquartered in Erlangen, Germany. | Health Technology |
Immatics US, Inc.
Immatics US, Inc. BiotechnologyHealth Technology Immatics US, Inc. develops adoptive cell therapies (ACT) for the treatment of cancer. The company’s ACT therapies are intended to use human T-cells that have been multiplied outside the body before being infused into a cancer patient. It also offers XPRESIDENT, a target discovery engine that enables users to identify, quantify, and prioritize tumor-associated peptides that are recognized by T-cells. The company was founded by Harpreet Singh-Jasuja, Toni Weinschenk, Niels Emmerich, Hans-George Rammensee, Steffen Walter, Peter Brossart and Hansjorg Schild in June 2015 and is headquartered in Houston, TX. | Health Technology |
Minaris Regenerative Medicine GmbH
Minaris Regenerative Medicine GmbH BiotechnologyHealth Technology apceth Biopharma GmbH operates as a contract development & manufacturing organization. The firm specializes in cell-based and gene therapy products (Advanced Therapy Medicinal Products, ATMPs). Its GMP services include quality management, quality control, assay development, process development, cell banking & formulation and project management. The company was founded in 2007 and is headquartered in Munich, Germany. | Health Technology |
iOmx Therapeutics AG
iOmx Therapeutics AG BiotechnologyHealth Technology iOmx Therapeutics AG develops immunotherapy treatments for cancer patients. It specializes in immuno oncology, drug development and cancer therapy. The company was founded by Nisit Khandelwal, Philipp Beckhove, Patrick Baeuerle, Sebastian Meier-Ewert and Elmar Maier in March 2016 and is headquartered in Munich, Germany. | Health Technology |